News

We’ve rounded up a list of important US Food and Drug Administration and US Department of Agriculture recalls from this past week.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

Evidence demonstrates that antimicrobial therapy with an anti-staphylococcal β-lactam antibiotic is the gold standard for treatment of SAB caused by MSSA, but confusion about which agent—particularly cefazolin versus an anti-staphylococcal penicillin—is preferred remains an unanswered question

The CDC hopes the case of a patient who was hospitalized in Maryland following a hospitalization in Kenya will help raise awareness of the importance of C auris screening.

Transitioning from a child born with HIV into an adult living with HIV often means less adherence to antiretroviral medication therapies and a lower level of viral suppression. A new study delves into some possible reasons why.

As outbreaks of vaccine-preventable diseases grow, it is important to review vaccination recommendations by age group.

Patients and health care professionals alike cite significant issues with education and emotion surrounding MDROs.

The research team deciphered that the nitazoxanide boosts the ability of specific viral sensors to detect Ebola when infected, which then sparks an antiviral immune response.

The approval marks the second drug approved under the Limited Population Pathway for Antibacterial and Antifungal Drugs.

Changes to Medicare funding, reimbursement, and proposed new legislation highlight new initiatives as investigators gain a better understanding of multidrug-resistant organism transmission.

Sterilization by radiation plus infection with Wolbachia bacteria in male mosquitoes can go a long way toward lowering the burden of deadly disease.

Investigators in the first human trial of a MERS-CoV candidate report strong immune responses and no serious adverse events, advancing the vaccine candidate to phase 1/2a and phase 2 trials.

We're failing to make sure cultures are indicated properly in catheterized patients, which can lead to serious disruptions of care.

The NIH-funded study will evaluate experimental adjuvants AF03 and Advax-CpG55.2 over an 18-month study period.

Research on a tenofovir disoproxil fumarate intravaginal ring for PrEP hit a hurdle when 8 of 12 women unexpectedly developed vaginal ulcers.

An independent monitoring board recommended early termination of the PALM trial after determining that 2 of the 4 experimental therapies were linked with better rates of survival.

Here is a look at infectious disease-related US Food and Drug Administration news from the week of August 4, 2019.

We’ve rounded up a list of important US Food and Drug Administration (FDA) and US Department of Agriculture (USDA) recalls from this past week.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

The Florida Department of Health has confirmed that a locally-acquired case of dengue has been documented in Miami-Dade County.

A UK study details a new way to prevent Legionnaires' disease and save energy.

From January 2019 to July 20, 2019, the Philippines has recorded 146,062 cases of dengue and 622 deaths, a 98% increase from the same period in 2018.

Blocking the transport of critical metals like zinc into the cell could be a way to prevent growth and therefore infection by Neisseria gonorrhoeae.

The committee voted 16 to 2 to recommend F/TAF for PrEP based upon data from the phase 3 DISCOVER study, which evaluated F/TAF in comparison with F/TDF.

The Ad26.ZEBOV, MVA-BN-Filo vaccine regimen will be evaluated in an open-label, single-arm study of 800 participants, including frontline health care workers.

Investigators exposed 6 genetically distinct, clinically relevant methicillin-resistant S aureus isolates to cigarette smoke to analyze how this contact altered specific virulence phenotypes.

An analysis of existing studies suggests prevalence of non-physician-sanctioned administration may be as high as 66%.

A study found no significant difference in outcomes between ceftazidime, carbapenems, and piperacillin-tazobactam as monotherapy for treating P aeruginosa, offering insight that may help antibiotic stewardship programs.